What to know about AMX0035
Oct 31, 2019•9 min•Season 1Ep. 19
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode of the Endpoints, Dr. Steve Perrin, CSO at the ALS Therapy Development Institute, sits down to talk about AMX0035, a drug consisting of a combination of two small molecule compounds: sodium phenylbutyrate and tauroursodeoxycholic acid (TUDCA). Amylyx, the sponsor of AMX0035, recently completed enrollment of a 132 participant phase 2 trial.
To learn more about the ALS Therapy Development Institute and our mission to end ALS, click here.
Support the show: https://www.als.net/donate/
See omnystudio.com/listener for privacy information.
For the best experience, listen in Metacast app for iOS or Android